Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Wujin, Li"'
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 17, Iss 5, Pp 1278-1287 (2021)
Background Programmed cell death protein 1 (PD-1) inhibitors are the first-line treatment for advanced non-small-cell lung cancer (NSCLC) patients. However, their efficacy in metastatic NSCLC patients remains controversial. Aim of the study The aim o
Externí odkaz:
https://doaj.org/article/9ca03693ba464261906a620705690b6c
Autor:
Wenshu Chen, Guanying Zheng, Jianyuan Huang, Lihuan Zhu, Wujin Li, Tianxing Guo, Yangyun Huang, Xiaojie Pan
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background Metastasis and disease refractoriness remain as major challenges for non-small cell lung cancer (NSCLC) treatment and understanding the underlying molecular mechanisms is of scientific and clinical value. Therefore, in this study,
Externí odkaz:
https://doaj.org/article/903c20dba4e14e2487a81d601202cecf
Autor:
Wenbao Lin, Jinlan Lin, Yangyun Huang, Lihuang Zhu, Wujin Li, Lilan Zhao, Xiaojie Pan, Tianxing Guo
Publikováno v:
Journal of Gastrointestinal Oncology. 13:2758-2768
Background Pembrolizumab has been approved by the Food and Drug Administration (FDA) for the first-line treatment of locally advanced or metastatic esophageal cancer. This study investigated the efficacy and safety of pembrolizumab combined with pacl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af1989952c2304e65b52f4e9d3d612a1
https://doi.org/10.21037/jgo-22-1196
https://doi.org/10.21037/jgo-22-1196
Autor:
Tianxing Guo, Zhenlong Zhang, Lihuan Zhu, Wenshu Chen, Yun Ding, Wujin Li, Yangyun Huang, Jianyuan Huang, Xiaojie Pan
Publikováno v:
Cancer Biology & Therapy
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Up until now, cancer refractoriness and distal organ metastatic disease remain as major obstacles for oncologists to achieve satisfactory therapeutic effects for lung adenocarcinoma patients. Previous studies indicated that TRIM55, which participates
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30f9df45126b911f90e0aac20f2f21f6
http://europepmc.org/articles/PMC8812808
http://europepmc.org/articles/PMC8812808
Autor:
Wujin Li, Jiawei Zhan, Jinbao Wang, Bizhong Xia, Bin-Bin Gao, Jun Liu, Chengjie Wang, Feng Zheng
Publikováno v:
Proceedings of the 30th ACM International Conference on Multimedia.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::393fda5a158fcc91b7a58f58a2c4e260
https://doi.org/10.1145/3503161.3548232
https://doi.org/10.1145/3503161.3548232
Autor:
Wujin Li, Mingdian Yu, Jiguang Zhang, Jianyuan Huang, Zhaoxian Lin, Jingbo Chen, Guicheng Jiang, Xing Lin
FANCI, as a member of the Fanconi anemia (FA) complementation group, normally associates with FANCD2 to play an important role in ribosome biogenesis and DNA repair. However, the correlation of FANCI to prognostic value and the molecular mechanism in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48d17bac4316a46c835793a9fead9944
https://doi.org/10.21203/rs.3.rs-1929672/v1
https://doi.org/10.21203/rs.3.rs-1929672/v1
Autor:
Long Chen, Tianxing Guo, Yun Ding, Wujin Li, Rongjia Lin, Lihuan Zhu, Yangyun Huang, jinlan Lin, Ji-guang Zhang, Xiaojie Pan
Publikováno v:
J Thorac Dis
Background Immune checkpoint inhibitors (ICIs) provided a paradigm shift for advanced non-small cell lung cancer (NSCLC) treatment and improved the clinical prognosis of such patients. Pembrolizumab is a humanized anti-programmed death cell protein 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::77839c9fc953694d89d08c3d45d7bd44
https://doi.org/10.21037/jtd-20-3413
https://doi.org/10.21037/jtd-20-3413
Publikováno v:
Computational and mathematical methods in medicine. 2022
Background. Lung adenocarcinoma (LUAD) is a major cause for global cancer-related deaths. Research reports demonstrate that lymph node metastasis (LNM) is pertinent to the survival rate of LUAD patients, and crux lies in the lack of biomarkers that c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::975d010f3a2b3ce208cd0a4ec93cd8ef
https://pubmed.ncbi.nlm.nih.gov/35836921
https://pubmed.ncbi.nlm.nih.gov/35836921
Publikováno v:
Hum Vaccin Immunother
BACKGROUND: Programmed cell death protein 1 (PD-1) inhibitors are the first-line treatment for advanced non-small-cell lung cancer (NSCLC) patients. However, their efficacy in metastatic NSCLC patients remains controversial. AIM OF THE STUDY: The aim
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::af2022909508f5b19c86beba60bc78d5
https://doi.org/10.1080/21645515.2020.1823779
https://doi.org/10.1080/21645515.2020.1823779
Publikováno v:
Biochemical and Biophysical Research Communications. 530:624-631
Long noncoding RNAs (lncRNAs) have been identified to be critical regulator for various human diseases and emerging evidence illustrate the essential function of lncRNAs in the non-small cell lung cancer (NSCLC). Here, our research team tried to iden
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6f8b506cd5c5ab4c6de56f25c36e7fe7
https://doi.org/10.1016/j.bbrc.2020.07.044
https://doi.org/10.1016/j.bbrc.2020.07.044